These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11181343)

  • 1. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.
    Clemons KV; Lutz JE; Stevens DA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):686-9. PubMed ID: 11181343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.
    Barchiesi F; Spreghini E; Schimizzi AM; Maracci M; Giannini D; Carle F; Scalise G
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3312-6. PubMed ID: 15328090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis.
    Clemons KV; Lutz JE; Stevens DA
    Microbes Infect; 2001 Jan; 3(1):3-10. PubMed ID: 11226849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis.
    Lutz JE; Clemons KV; Stevens DA
    J Antimicrob Chemother; 2000 Sep; 46(3):437-42. PubMed ID: 10980171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    Int J Antimicrob Agents; 2004 Sep; 24(3):219-25. PubMed ID: 15325424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
    Pappas PG; Chetchotisakd P; Larsen RA; Manosuthi W; Morris MI; Anekthananon T; Sungkanuparph S; Supparatpinyo K; Nolen TL; Zimmer LO; Kendrick AS; Johnson P; Sobel JD; Filler SG
    Clin Infect Dis; 2009 Jun; 48(12):1775-83. PubMed ID: 19441980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice.
    Doherty TM; Sher A
    J Immunol; 1998 Jun; 160(11):5428-35. PubMed ID: 9605144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
    Silva EG; Paula CR; de Assis Baroni F; Gambale W
    Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
    Khan MA; Nasti TH; Owais M
    J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
    Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
    J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
    Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
    J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
    Magalhães TFF; Costa MC; Holanda RA; Ferreira GF; Carvalho VSD; Freitas GJC; Ribeiro NQ; Emídio ECP; Carmo PHF; de Brito CB; de Souza DG; Rocha CEV; Paixão TA; de Resende-Stoianoff MA; Santos DA
    Med Mycol; 2020 Aug; 58(6):835-844. PubMed ID: 31919505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.